In addition, INBRX-106, a recombinant, humanized, hexavalent antibody that stimulates OX40, is being tested in a phase I study in combination with pembrolizumab in patients with pretreated locally advanced or metastatic solid tumors, including HNSCC (NCT04198766). Here, TNFRSF4 is linked to head and neck squamous cell carcinoma.